Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients

7Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that remains incurable. Although the etiologies of ALS are diverse and the precise pathogenic mechanisms are not fully understood, approximately 20% of ALS cases are caused by genetic factors. Therefore, advancing targeted gene therapies holds significant promise, at least for the 20% of ALS patients with genetic etiologies. In this review, we summarize the main strategies and techniques of current ALS gene therapies based on ALS risk genes, and review recent findings from animal studies and clinical trials. Additionally, we highlight ALS-related genes with well-understood pathogenic mechanisms and the potential of numerous emerging gene-targeted therapeutic approaches for ALS.

Cite

CITATION STYLE

APA

Xie, Q., Li, K., Chen, Y., Li, Y., Jiang, W., Cao, W., … Deng, B. (2025, December 1). Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients. Translational Neurodegeneration. BioMed Central Ltd. https://doi.org/10.1186/s40035-025-00477-6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free